The earnings call presented a mix of positive developments and challenges. Significant achievements include growth in the infant formula and OTC brand sectors, successful cost-saving initiatives, and improved EPS. However, these were tempered by declines in gross margin, challenges in the infant formula market, and soft seasonal trends impacting sales. Despite these challenges, the company's strategic initiatives seem to be gaining traction, suggesting a cautiously optimistic outlook.

Company Guidance

During the Perrigo Q2 2025 earnings call, the company provided guidance and updates on their strategic Three-S Plan, focusing on stabilizing, streamlining, and strengthening their operations. For the second quarter, Perrigo reported flat organic net sales growth compared to the previous year, with OTC brand growth of 3.6%. Year-to-date, organic growth was nearly 1% excluding prior impacts. The company's infant formula business saw a 9% net sales increase, while their diversified portfolio demonstrated resilience in a challenging consumer environment. Despite a decline in gross margin driven by divestitures and production issues, organic operating income remained flat, and EPS grew 7.5%, or 12.5% organically. Looking forward, Perrigo reaffirmed its full-year EPS outlook, projecting strong double-digit growth, and emphasized continued investments in brand-building and demand generation to bolster their market position.

Infant Formula Business Growth

The infant formula business net sales grew 9% year-over-year, led by store brand formula. The store brand and contract business collectively were up more than 30%.

OTC Brand Growth

OTC brands delivered organic net sales growth of 3.6% year-over-year. Jungle Formula grew 14% and achieved record market share in the U.K., while Compeed grew 6% and achieved record share in France, Spain, and Italy.

Project Energize and Supply Chain Reinvention

Project Energize is generating an annual run rate gross savings of $159 million, and the Supply Chain Reinvention program is on track to deliver $150 million to $200 million in benefits by year-end.

EPS Growth

EPS in the quarter grew 7.5% or 12.5% organically, and is up more than 50% organically year-to-date.

U.S. Store Brand OTC Improvements

New business awards outpaced lost distribution for the first time since 2024. Perrigo allergy product sales at a top retailer are up almost 19% year-to-date.

Perrigo Company (PRGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PRGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.76 / -	0.81	―	―	―
Aug 06, 2025	2025 (Q2)	0.59 / 0.57	0.53	7.55% (+0.04)
May 07, 2025	2025 (Q1)	0.57 / 0.60	0.29	106.90% (+0.31)
Feb 27, 2025	2024 (Q4)	0.92 / 0.93	0.86	8.14% (+0.07)	―	―
Nov 06, 2024	2024 (Q3)	0.81 / 0.81	0.64	26.56% (+0.17)
Aug 02, 2024	2024 (Q2)	0.47 / 0.53	0.63	-15.87% (-0.10)
May 07, 2024	2024 (Q1)	0.23 / 0.29	0.45	-35.56% (-0.16)
Feb 27, 2024	2023 (Q4)	0.83 / 0.86	0.75	14.67% (+0.11)
Nov 07, 2023	2023 (Q3)	0.63 / 0.64	0.56	14.29% (+0.08)
Aug 08, 2023	2023 (Q2)	0.51 / 0.63	0.43	46.51% (+0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PRGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$26.62	$23.61	-11.31%
May 07, 2025	$24.42	$26.13	+7.00%
Feb 27, 2025	$23.63	$28.40	+20.19%
Nov 06, 2024	$24.59	$26.49	+7.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.